Synairgen plc Release: Notice Of Interim Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Southampton, UK, 17 September 2014: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, will announce its interim results for the six months ended 30 June 2014 on Thursday 25 September 2014.

A meeting for analysts will be held at 10:30am GMT at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

For further information, please contact:

Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800

finnCap
Geoff Nash, Christopher Raggett (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701

Notes for Editors

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology Biobank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The Biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen’s business strategy is the realisation of value via licensing transactions – validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

Help employers find you! Check out all the jobs and post your resume.

Back to news